相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells
A. H. Daneshmanesh et al.
LEUKEMIA (2012)
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease
Davide Bagnara et al.
BLOOD (2011)
Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis
Alessandra Gentile et al.
CANCER RESEARCH (2011)
Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma
Marc A. Weniger et al.
CLINICAL CANCER RESEARCH (2011)
ROR1 expression is not a unique marker of CLL
Gabor Barna et al.
HEMATOLOGICAL ONCOLOGY (2011)
Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies
Jiahui Yang et al.
PLOS ONE (2011)
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes
Masanori Onda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
Rosa Lapalombella et al.
BLOOD (2010)
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
Michael Hudecek et al.
BLOOD (2010)
Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression
Christian Bogner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells
Aniruddha Choudhury et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin
Robert Sarnovsky et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2010)
A Recombinant Immunotoxin Targeting CD22 With Low Immunogenicity, Low Nonspecific Toxicity, and High Antitumor Activity in Mice
Johanna K. Hansen et al.
JOURNAL OF IMMUNOTHERAPY (2010)
ABT-737 Overcomes Resistance to Immunotoxin-Mediated Apoptosis and Enhances the Delivery of Pseudomonas Exotoxin-Based Proteins to the Cell Cytosol
Roberta Traini et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Stat3 Activates the Receptor Tyrosine Kinase Like Orphan Receptor-1 Gene in Chronic Lymphocytic Leukemia Cells
Ping Li et al.
PLOS ONE (2010)
CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies
Ralph F. Alderson et al.
CLINICAL CANCER RESEARCH (2009)
Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
Robert J. Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Variable Contribution of Monoclonal Antibodies to ADCC in patients with chronic lymphocytic leukemia
James Weitzman et al.
LEUKEMIA & LYMPHOMA (2009)
Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells
Amani Mankai et al.
CANCER RESEARCH (2008)
Differential cellular internalization of anti-CD19 and-CD22 immunotoxins results in different cytotoxic activity
Xing Du et al.
CANCER RESEARCH (2008)
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia
Sivasubramanian Baskar et al.
CLINICAL CANCER RESEARCH (2008)
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
Amir H. DaneshManesh et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal,antigen and receptor for Wnt5a
Tetsuya Fukuda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins
Xing Du et al.
BLOOD (2008)
Immunotoxins in the treatment of hematologic malignancies
Robert J. Kreitman et al.
CURRENT DRUG TARGETS (2006)
Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity
Tom van Meerten et al.
CLINICAL CANCER RESEARCH (2006)
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-Cell malignancies
RJ Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance
JP MacKeigan et al.
NATURE CELL BIOLOGY (2005)
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins
T Decker et al.
BLOOD (2004)
Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells
U Klein et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia
A Rosenwald et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
分享论文
